Total trials
81
Active
22
Phase 3
8
Total enrollment
3,240
Pipeline matrix
Showing 40 of 46 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| N-803 | — | — | — | 17 | |||
| N-803 and BCG | — | — | — | — | 2 | ||
| Docetaxel | — | — | — | — | 2 | ||
| Tislelizumab | — | — | — | — | — | 1 | |
| Prior failed checkpoint inhibitor | — | — | — | — | — | 1 | |
| Nogapendekin Alfa Inbakicept | — | — | — | 4 | |||
| nab-Paclitaxel | — | — | — | — | 21 | ||
| Cyclophosphamide | — | — | — | — | 24 | ||
| Gemcitabine | — | — | — | — | 5 | ||
| PD-L1 t-haNK | — | — | — | — | 4 | ||
| rituximab | — | — | — | — | 3 | ||
| CD19 t-haNK- IV Administration | — | — | — | — | — | 2 | |
| BCG | — | — | — | — | 2 | ||
| Leucovorin | — | — | — | — | — | 20 | |
| bevacizumab | — | — | — | — | — | 17 | |
| 5-Fluorouracil | — | — | — | — | — | 15 | |
| Cisplatin | — | — | — | — | — | 10 | |
| Aldoxorubicin HCl | — | — | — | — | — | 7 | |
| M-CENK | — | — | — | — | — | 3 | |
| hAd5-HPV Vaccine | — | — | — | — | — | 1 | |
| Anktiva | — | — | — | — | — | 1 | |
| Irinotecan liposome | — | — | — | — | — | 1 | |
| N-803 and Gemcitabine | — | — | — | — | — | 1 | |
| N-803 + Pembrolizumab | — | — | — | — | — | 1 | |
| N-803 + Nivolumab | — | — | — | — | — | 1 | |
| N-803 + Atezolizumab | — | — | — | — | — | 1 | |
| N-803 + Avelumab | — | — | — | — | — | 1 | |
| N-803 + Durvalumab | — | — | — | — | — | 1 | |
| N-803 + Pembrolizumab + PD-L1 t-haNK | — | — | — | — | — | 1 | |
| N-803 + Nivolumab + PD-L1 t-haNK | — | — | — | — | — | 1 | |
| N-803 + Atezolizumab + PD-L1 t-haNK | — | — | — | — | — | 1 | |
| N-803 + Avelumab + PD-L1 t-haNK | — | — | — | — | — | 1 | |
| N-803 + Durvalumab + PD-L1 t-haNK | — | — | — | — | — | 1 | |
| N-803 + Docetaxel + Pembrolizumab | — | — | — | — | — | 1 | |
| N-803 + Docetaxel + Nivolumab | — | — | — | — | — | 1 | |
| Intravesical Recombinant Mycobacterium | — | — | — | — | — | 1 | |
| CD19 t-haNK | — | — | — | — | — | 3 | |
| N803 | — | — | — | — | — | 1 | |
| CD19t-haNK suspension | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | — | 1 |
6 more active programs hidden
Next readouts
- 2024-10-01
- 2025-10-13
- 2026-05-15
- 2026-05-31
- 2026-07
- 2026-09-30
- 2026-10
- 2026-11
- 2027-05
- 2027-05-25
Top conditions
- Pancreatic Cancer6
- Covid194
- COVID-194
- NMIBC3
- Sepsis3
- Lymphopenia3
- Merkel Cell Carcinoma3
- Solid Tumor2
Frequently asked questions about ImmunityBio, Inc.
- How many clinical trials does ImmunityBio, Inc. have on ClinicalTrials.gov?
- ImmunityBio, Inc. is listed as the lead sponsor on 81 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
- How many of ImmunityBio, Inc.'s trials are in Phase 3?
- 8 of ImmunityBio, Inc.'s trials are in Phase 3, spread across 46 active drug programs.
- What therapeutic areas does ImmunityBio, Inc. focus on?
- ImmunityBio, Inc.'s most-studied conditions on ClinicalTrials.gov are Pancreatic Cancer, Covid19, COVID-19, NMIBC, Sepsis.
- When are ImmunityBio, Inc.'s next clinical trial readouts?
- ImmunityBio, Inc. has 10 upcoming primary-completion readouts tracked here; the soonest is “QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer”, expected around 2024-10-01.